Reprogramming of stroma-derived chemokine networks drives the loss of tissue organization in nodal B cell lymphoma.
Saved in:
| Title: | Reprogramming of stroma-derived chemokine networks drives the loss of tissue organization in nodal B cell lymphoma. |
|---|---|
| Authors: | Czernilofsky F; Department of Internal Medicine V, Hematology, Oncology and Rheumatology, University Hospital Heidelberg, Heidelberg, Germany.; European Molecular Biology Laboratory (EMBL), Heidelberg, Germany.; Molecular Medicine Partnership Unit (MMPU), Heidelberg, Germany., Mathioudaki A; European Molecular Biology Laboratory (EMBL), Heidelberg, Germany.; Molecular Medicine Partnership Unit (MMPU), Heidelberg, Germany.; Faculty of Biosciences, University of Heidelberg, Heidelberg, Germany.; Division of AI in Oncology, German Cancer Research Centre (DKFZ), Heidelberg, Germany., Jopp-Saile L; Faculty of Biosciences, University of Heidelberg, Heidelberg, Germany.; Heidelberg Institute for Stem Cell Technology and Experimental Medicine (HI-STEM gGmbH), Heidelberg, Germany.; Division of Stem Cells and Cancer, German Cancer Research Centre (DKFZ), Heidelberg, Germany.; Berlin Institute of Health (BIH), Charité Universitätsmedizin Berlin, Berlin, Germany.; Max Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin Institute for Medical Systems Biology, Berlin, Germany., Lutz R; Department of Internal Medicine V, Hematology, Oncology and Rheumatology, University Hospital Heidelberg, Heidelberg, Germany.; Heidelberg Institute for Stem Cell Technology and Experimental Medicine (HI-STEM gGmbH), Heidelberg, Germany.; Division of Stem Cells and Cancer, German Cancer Research Centre (DKFZ), Heidelberg, Germany., Vonficht D; Faculty of Biosciences, University of Heidelberg, Heidelberg, Germany.; Heidelberg Institute for Stem Cell Technology and Experimental Medicine (HI-STEM gGmbH), Heidelberg, Germany.; Division of Stem Cells and Cancer, German Cancer Research Centre (DKFZ), Heidelberg, Germany., Wang X; Department of Internal Medicine V, Hematology, Oncology and Rheumatology, University Hospital Heidelberg, Heidelberg, Germany.; European Molecular Biology Laboratory (EMBL), Heidelberg, Germany.; Molecular Medicine Partnership Unit (MMPU), Heidelberg, Germany., Schniederjohann C; Department of Internal Medicine V, Hematology, Oncology and Rheumatology, University Hospital Heidelberg, Heidelberg, Germany.; European Molecular Biology Laboratory (EMBL), Heidelberg, Germany.; Molecular Medicine Partnership Unit (MMPU), Heidelberg, Germany.; Faculty of Biosciences, University of Heidelberg, Heidelberg, Germany.; Department of Hematology, Oncology and Clinical Immunology, Medical Faculty and University Hospital Düsseldorf, Düsseldorf, Germany.; Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf (CIO ABCD), Düsseldorf, Germany., Voehringer H; European Molecular Biology Laboratory (EMBL), Heidelberg, Germany.; Molecular Medicine Partnership Unit (MMPU), Heidelberg, Germany., Roider T; Department of Internal Medicine V, Hematology, Oncology and Rheumatology, University Hospital Heidelberg, Heidelberg, Germany.; European Molecular Biology Laboratory (EMBL), Heidelberg, Germany.; Molecular Medicine Partnership Unit (MMPU), Heidelberg, Germany., Baertsch MA; Department of Internal Medicine V, Hematology, Oncology and Rheumatology, University Hospital Heidelberg, Heidelberg, Germany.; Department of Pathology, Stanford University School of Medicine, Stanford, CA, USA., Rodemer C; Department of Internal Medicine V, Hematology, Oncology and Rheumatology, University Hospital Heidelberg, Heidelberg, Germany., Löffler-Wirth H; Interdisciplinary Centre for Bioinformatics (IZBI), University of Leipzig, Leipzig, Germany., Grau M; Department of Medicine A, Hematology, Oncology and Pneumology, University Hospital Münster, Münster, Germany., Fitzgerald D; Department of Internal Medicine V, Hematology, Oncology and Rheumatology, University Hospital Heidelberg, Heidelberg, Germany.; European Molecular Biology Laboratory (EMBL), Heidelberg, Germany.; Molecular Medicine Partnership Unit (MMPU), Heidelberg, Germany.; Faculty of Biosciences, University of Heidelberg, Heidelberg, Germany., Mammen J; Department of Internal Medicine V, Hematology, Oncology and Rheumatology, University Hospital Heidelberg, Heidelberg, Germany.; European Molecular Biology Laboratory (EMBL), Heidelberg, Germany.; Molecular Medicine Partnership Unit (MMPU), Heidelberg, Germany., Kosla J; Division of Chronic Inflammation and Cancer, German Cancer Research Center Heidelberg (DKFZ), Heidelberg, Germany.; Laboratory of Integrative Biology, Institute of Molecular Genetics of the Czech Academy of Sciences, Prague, Czech Republic., Liebers N; Department of Hematology, Oncology and Clinical Immunology, Medical Faculty and University Hospital Düsseldorf, Düsseldorf, Germany.; Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf (CIO ABCD), Düsseldorf, Germany., Bruch PM; Department of Internal Medicine V, Hematology, Oncology and Rheumatology, University Hospital Heidelberg, Heidelberg, Germany.; European Molecular Biology Laboratory (EMBL), Heidelberg, Germany.; Molecular Medicine Partnership Unit (MMPU), Heidelberg, Germany.; Department of Hematology, Oncology and Clinical Immunology, Medical Faculty and University Hospital Düsseldorf, Düsseldorf, Germany.; Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf (CIO ABCD), Düsseldorf, Germany., Ordoñez-Rueda D; European Molecular Biology Laboratory (EMBL), Heidelberg, Germany., Brobeil A; Department of Pathology, University Hospital Heidelberg, Heidelberg, Germany., Mechtersheimer G; Department of Pathology, University Hospital Heidelberg, Heidelberg, Germany., Pabst C; Department of Internal Medicine V, Hematology, Oncology and Rheumatology, University Hospital Heidelberg, Heidelberg, Germany.; European Molecular Biology Laboratory (EMBL), Heidelberg, Germany.; Molecular Medicine Partnership Unit (MMPU), Heidelberg, Germany., Müller-Tidow C; Department of Internal Medicine V, Hematology, Oncology and Rheumatology, University Hospital Heidelberg, Heidelberg, Germany.; European Molecular Biology Laboratory (EMBL), Heidelberg, Germany.; Molecular Medicine Partnership Unit (MMPU), Heidelberg, Germany., Trumpp A; Heidelberg Institute for Stem Cell Technology and Experimental Medicine (HI-STEM gGmbH), Heidelberg, Germany.; Division of Stem Cells and Cancer, German Cancer Research Centre (DKFZ), Heidelberg, Germany., Seifert M; Department of Hematology, Oncology and Clinical Immunology, Medical Faculty and University Hospital Düsseldorf, Düsseldorf, Germany.; Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf (CIO ABCD), Düsseldorf, Germany., Neumann F; Kite, a Gilead Company, Santa Monica, CA, USA., Heikenwälder M; Division of Chronic Inflammation and Cancer, German Cancer Research Center Heidelberg (DKFZ), Heidelberg, Germany., Benes V; European Molecular Biology Laboratory (EMBL), Heidelberg, Germany., Huber W; European Molecular Biology Laboratory (EMBL), Heidelberg, Germany.; Molecular Medicine Partnership Unit (MMPU), Heidelberg, Germany., Distler J; Department of Rheumatology, Medical Faculty and University Hospital Düsseldorf, Düsseldorf, Germany., Lenz G; Department of Medicine A, Hematology, Oncology and Pneumology, University Hospital Münster, Münster, Germany., Binder H; Interdisciplinary Centre for Bioinformatics (IZBI), University of Leipzig, Leipzig, Germany., Siebert R; Institute of Human Genetics, Ulm University and Ulm University Medical Center, Ulm, Germany., Nolan GP; Department of Pathology, Stanford University School of Medicine, Stanford, CA, USA., Gerstung M; Division of AI in Oncology, German Cancer Research Centre (DKFZ), Heidelberg, Germany., Zaugg JB; European Molecular Biology Laboratory (EMBL), Heidelberg, Germany. judith.zaugg@unibas.ch.; Molecular Medicine Partnership Unit (MMPU), Heidelberg, Germany. judith.zaugg@unibas.ch.; Department of Biomedicine, University of Basel and University Hospital Basel, Basel, Switzerland. judith.zaugg@unibas.ch., Hübschmann D; Heidelberg Institute for Stem Cell Technology and Experimental Medicine (HI-STEM gGmbH), Heidelberg, Germany. d.huebschmann@dkfz-heidelberg.de.; Computational Oncology Group (CO), Molecular Precision Oncology Program (MPOP), National Center for Tumor Diseases (NCT) and German Cancer Research Center (DKFZ), Heidelberg, Germany. d.huebschmann@dkfz-heidelberg.de.; Innovation and Service Unit for Bioinformatics and Precision Medicine, German Cancer Research Center (DKFZ), Heidelberg, Germany. d.huebschmann@dkfz-heidelberg.de.; Division of Translational Precision Medicine, Institute of Human Genetics, University of Heidelberg, Heidelberg, Germany. d.huebschmann@dkfz-heidelberg.de.; German Cancer Consortium (DKTK), Heidelberg, Germany. d.huebschmann@dkfz-heidelberg.de., Haas S; Berlin Institute of Health (BIH), Charité Universitätsmedizin Berlin, Berlin, Germany. simon.haas@bih-charite.de.; Max Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin Institute for Medical Systems Biology, Berlin, Germany. simon.haas@bih-charite.de.; German Cancer Consortium (DKTK), Partner Site Berlin and German Cancer Research Center (DKFZ), Heidelberg, Germany. simon.haas@bih-charite.de.; Precision Healthcare University Research Institute, Queen Mary University of London, London, UK. simon.haas@bih-charite.de.; Cluster of Excellence ImmunoPreCept, Charité Universitätsmedizin Berlin, Berlin, Germany. simon.haas@bih-charite.de., Dietrich S; Department of Internal Medicine V, Hematology, Oncology and Rheumatology, University Hospital Heidelberg, Heidelberg, Germany. sascha.dietrich@embl.de.; European Molecular Biology Laboratory (EMBL), Heidelberg, Germany. sascha.dietrich@embl.de.; Molecular Medicine Partnership Unit (MMPU), Heidelberg, Germany. sascha.dietrich@embl.de.; Department of Hematology, Oncology and Clinical Immunology, Medical Faculty and University Hospital Düsseldorf, Düsseldorf, Germany. sascha.dietrich@embl.de.; Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf (CIO ABCD), Düsseldorf, Germany. sascha.dietrich@embl.de. |
| Source: | Nature cancer [Nat Cancer] 2026 Mar; Vol. 7 (3), pp. 538-552. Date of Electronic Publication: 2026 Mar 25. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101761119 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2662-1347 (Electronic) Linking ISSN: 26621347 NLM ISO Abbreviation: Nat Cancer Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
